New from the distributors of Strivectin is Amatokin, an anti-ageing cream that claims revolutionary properties due its utilisation of stem cell technology.
Manufacturer Voss Laboratories says Amatokin is the first topical compound to highlight the expression of stem cell markers in the actual skin rather than skin cell models. The Amatokin peptide is said to trigger the skin’s stem cell driven potential for regeneration. This signalling peptide is said to make contact with the nucleated epidermal cell receptors and where there is damage send a signal strong enough to initiate the synthesis and expression of cytokines IL-6 and IL-8 and of a growth factor and growth factor gene cascade that rouses dormant stem cells located in the basal epidermal membrane into action. The newly roused cells are said to divide into a duplicate epidermal ‘replacement’ stem cell and a transit amplifying ‘daughter’ cell, with the ensuing migration, division and differentiation resulting in the repopulation of epidermal tissue, infusing the epidermis with newborn, fully differentiated keratinocytes.
Voss Laboratories says Amatokin does not penetrate the dermis, acting only on the upper layers of nucleated epidermal cells, so there is no systemic absorption.
The product was originally developed in St Petersburg, Russia to help heal burn victims, and has subsequently been found to eliminate deeper wrinkles with long lasting results. According to Voss: “Amatokin’s method of action, actualizing the natural stem cell rejuvenation potential provides benefits to ageing and damaged skin way beyond what a customer can reasonably expect from any other topical skin care product or technology.”
